Jyoti Bala
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jyoti Bala has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Hoshang Jehangir Unwalla
Department of Cellular and Molecular Medicine, Herbert Wertheim College of Medicine, Florida International University, Miami, USA
2 shared publications - Ajeet Kaushik
Florida Polytechnic University
1 shared publication - Arti Vashist
Florida International University
1 shared publication M. Agudelo
Department of Immunology, Institute of NeuroImmune Pharmacology, Herbert Wertheim College of Medicine, Florida International University, Miami, FL, USA
1 shared publicationM. Nair
Department of Immunology, Institute of NeuroImmune Pharmacology, Herbert Wertheim College of Medicine, Florida International University, Miami, FL, USA
1 shared publicationMadhavan Nair
Department of Immunology, Institute of NeuroImmune Pharmacology, Centre for Personalized Nanomedicine, Herbert Wertheim College of Medicine, Florida International University Miami Florida 33199 USA
1 shared publication
Latest Publications
- Open Access
- 22 May 2018
- Published by Springer Nature in Scientific Reports
- Vol. 8 (1) , 7984
Cigarette smoke promotes HIV infection of primary bronchial epithelium and additively suppresses CFTR function
Recurrent lung infections are a common cause of morbidity and mortality in people living with HIV and this is exacerbated in smokers even when administered combination antiretroviral therapy (cART). The incidence of pneumonia is increased with smoking and treatment interruption and is directly dependent on viral load in patients when adjusted for CD4 counts. CFTR dysfunction plays an important role in aberrant airway innate immunity as it is pivotal in regulating mucociliary clearance (MCC) rates and other antibacterial mechanisms of the airway. In our earlier work, we have demonstrated that bronchial epithelium expresses canonical HIV receptors CD4, CCR5 and CXCR4 and can be infected with HIV. HIV Tat suppresses CFTR mRNA and function via TGF-β signaling. In the present study, we demonstrate that cigarette smoke (CS) potentiates HIV infection of bronchial epithelial cells by upregulating CD4 and CCR5 expression. HIV and CS individually and additively suppress CFTR biogenesis and function, possibly explaining the increased incidence of lung infections in HIV patients and its exacerbation in HIV smokers.
- 22 May 2018
- Published by Springer Nature in Scientific Reports
- Vol. 8 (1) , 7984
Open AccessCigarette smoke promotes HIV infection of primary bronchial epithelium and additively suppresses CFTR function
Recurrent lung infections are a common cause of morbidity and mortality in people living with HIV and this is exacerbated in smokers even when administered combination antiretroviral therapy (cART). The incidence of pneumonia is increased with smoking and treatment interruption and is directly dependent on viral load in patients when adjusted for CD4 counts. CFTR dysfunction plays an important role in aberrant airway innate immunity as it is pivotal in regulating mucociliary clearance (MCC) rates and other antibacterial mechanisms of the airway. In our earlier work, we have demonstrated that bronchial epithelium expresses canonical HIV receptors CD4, CCR5 and CXCR4 and can be infected with HIV. HIV Tat suppresses CFTR mRNA and function via TGF-β signaling. In the present study, we demonstrate that cigarette smoke (CS) potentiates HIV infection of bronchial epithelial cells by upregulating CD4 and CCR5 expression. HIV and CS individually and additively suppress CFTR biogenesis and function, possibly explaining the increased incidence of lung infections in HIV patients and its exacerbation in HIV smokers.
- 14 November 2017
- Published by Royal Society of Chemistry (RSC)
- p. 94-108
Nanogels for Brain Drug Delivery
Emerging nanotechnology and targeted drug delivery approaches have come up with alternative delivery carriers for better therapeutics. Nanogels are also known as hydrogel nanoparticles that have gained significant attention as a nanocarrier system. The brain, the most crucial and sensitive organ of the human body, is well known to be protected by a strong blood brain barrier (BBB), which shields it from any foreign substances. Numerous drugs are unable to cross this strong barrier and thus restricts the use of newly developed drugs to be utilized for brain disease. The diverse spectrum of nanogel-based drug delivery systems have shown promising results in transporting many therapeutics and bioactives across the BBB as well as drug delivery for various neurological disorders. The present chapter is an attempt to highlight the various nanogel systems exploited for brain drug delivery.
- 14 November 2017
- Published by Royal Society of Chemistry (RSC)
- p. 94-108
Nanogels for Brain Drug Delivery
Emerging nanotechnology and targeted drug delivery approaches have come up with alternative delivery carriers for better therapeutics. Nanogels are also known as hydrogel nanoparticles that have gained significant attention as a nanocarrier system. The brain, the most crucial and sensitive organ of the human body, is well known to be protected by a strong blood brain barrier (BBB), which shields it from any foreign substances. Numerous drugs are unable to cross this strong barrier and thus restricts the use of newly developed drugs to be utilized for brain disease. The diverse spectrum of nanogel-based drug delivery systems have shown promising results in transporting many therapeutics and bioactives across the BBB as well as drug delivery for various neurological disorders. The present chapter is an attempt to highlight the various nanogel systems exploited for brain drug delivery.